DMD Trial Results Demonstrate Decrease in Creatine Kinase LevelsJuly 10th 2018
Results of a Phase 1/2a gene therapy clinical trial in children with Duchenne muscular dystrophy (DMD) revealed a significant decrease in levels of serum creatine kinase, an enzyme biomarker associated with muscle damage caused by DMD.
CAR-T Cells Can Increase Clinical Remission Rates in Multiple Myeloma PatientsAugust 2nd 2017
The new immunotherapy of chimeric antigen receptor (CAR)-T cells has demonstrated the ability to increase clinical remission in multiple myeloma patients by targeting the B-cell maturation protein that participates in disease progression.
Novartis' CAR-T Therapy for Pediatric Leukemia to Face FDA Advisory PanelJuly 11th 2017
Novartis’ chimeric antigen receptor T-cell (CAR-T) therapy for treating pediatric leukemia is on the cusp of being the first FDA-approved gene therapy, which will lead to new developments and utilizations of CAR-T therapy for treating other advanced blood cancers.